Pathological complete response after primary chemotherapy in a mother and daughter with hereditary breast carcinoma: Two case reports

European Journal of Gynaecological Oncology

Volumn 29, Issue 2, 2008, Pages 188-190

  Melichar, B ^a   Fridrichova P ^a   Lukesova S ^a   Mergancova J ^a   Urminska H ^a   Ryska A ^a   Foretova L ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

BRCA1; Hereditary breast carcinoma; Pathological complete response

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADULT; ARTICLE; BIOPSY; BREAST CARCINOMA; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MASTECTOMY; ONCOGENE; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXONS; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOTHERS; MUTATION; NUCLEAR FAMILY; PACLITAXEL; UBIQUITIN-PROTEIN LIGASES;

EID: 41849126056     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Veronesi U., Boyle P., Goldhirsch A., Orecchia R., Viale G.: "Breast cancer". Lancet, 2005, 365, 1727.
2. Early Breast Cancer Trialists Collaborative Group: "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials". Lancet, 2005, 365, 1687.
3. Estevez L.G., Gradishar W.J.: "Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer". Clin. Cancer Res., 2004, 10, 3249.
4. Kaufmann M., Hortobagyi G.N., Goldhirsch A., Scholl S., Makris A., Valagussa P. et al.: "Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update". J. Clin. Oncol., 2006, 24, 1940.
5. Chevallier B., Roche H., Olivier J.P., Chollet P., Hurteloup P.: "Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in high histologic response rate". Am. J. Clin. Oncol., 1993, 16, 223.
6. Chollet P., Amat S., Cure H., de Latour M., Le Bouedec G., Mouret-Reynier M.A. et al.: "Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer". Br. J. Cancer, 2002, 86, 1041.
7. Bear H.D., Anderson S., Smith R.E., Geyer C.E., Mamounas E.P., Fischer B. et al.: "Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27". J. Clin. Oncol., 2006, 24, 2019.
8. Machiavelli M.R., Romero A.O., Perez J.E., Lacava J.A., Dominguez M.E., Rodriguez R., et al.: "Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma". Cancer J. Sci. Am., 1998, 4, 125.
9. Thomas E., Holmes F.A., Smith T.L., Buzdar A.U., Frye D.K., Fraschini G., et al.: "The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial". J. Clin. Oncol., 2004, 22, 2294.
10. King M.C., Marks J.H., Mandell J.B.: "Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2". Science, 2003, 302, 643.
11. Robson M.E., Chappuis P.O., Satagopan J., Wong N., Boyd J., Goffin J.R., et al.: "A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment". Breast Cancer Res., 2004, 6, R8.
12. Goffin J.R., Chappuis P.O., Begin L.R., Wong N., Brunet J.S., Hamel N., et al.: "Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma. 10-year follow-up data". Cancer, 2003, 97, 527.
13. Rubin S.C., Benjamin I., Benbakht K., Takahashi H., Morgan M.A., LiVolsi V.A., et al.: "Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1". N. Engl. J. Med., 1996, 335, 1413.
14. Boyd J., Sonoda Y., Federici M.G., Bogomolniy F., Rhei E., Maresco D.L., et al.: "Clinicopathologic features of BRCA-linked and sporadic ovarian cancer". JAMA, 2000, 283, 2260.
15. Cass I., Baldwin R.L., Varkes T., Moslehi R., Narod S.A., Karlan B.Y.: "Improved survival in women with BRCA-associated ovarian carcinoma". Cancer, 2003, 97, 2187.
16. Cleator S., Heller W., Coombes C.R.: "Triple-negative breast cancer: therapeutic options". Lancet Oncol., 2007, 8, 235.
17. Chappuis P.O., Goffin J., Wong N., Perret C., Ghadirian P., Tonin P.N., et al.: "A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer". J. Med. Genet., 2002, 39, 608.
18. Warner E., Trudeau M., Holloway C.: "Sensitivity of BRCA-1-related breast cancer to neoadjuvant chemotherapy: practical implications". Breast J., 2003, 9, 507.
19. Kennedy R.D., Quinn J.E., Mullan P.B., Johnston P.G., Harkin D.P.: "The role of BRCA1 in the cellular response to chemotherapy". J. Natl. Cancer Inst., 2004, 96, 1659.
20. Citron M.L., Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gradishar W.J., et al.: "Randomized trial, of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741". J. Clin. Oncol., 2003, 21, 1431.
21. Henderson I.C., Berry D., Demetri G., Cirrincione C., Goldstein L., Martino S., et al.: "Improved outcomes from adding sequential paclitaxel but not from the escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer". J. Clin. Oncol., 2003, 21, 976.
22. Green M.C., Buzdar A.U., Smith T., Ibrahim N.K., Valero V., Rosales M.F., et al.: "Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel with paclitaxel once every 3 weeks". J. Clin. Oncol., 2005, 23, 5983.